We are thrilled to announce positive inital data demonstrating nasal delivery of our mRNA lead candidate ETH47 for the treatment of uncontrolled asthma. ETH47 resulted in a dose-dependent increase in target protein expression in the nasal cavity and was generally safe and well-tolerated and a full data readout is expected in Q3 this year. Learn more: https://lnkd.in/dNkG7XCP
Ethris
Biotechnologie
Ethris is paving a new path from genes to therapeutic proteins using its proprietary messenger RNA technology platform.
Info
Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners.
- Website
-
https://www.ethris.com/
Externer Link zu Ethris
- Branche
- Biotechnologie
- Größe
- 51–200 Beschäftigte
- Hauptsitz
- Planegg
- Art
- Privatunternehmen
- Gegründet
- 2009
- Spezialgebiete
- Biotechnology, mRNA, LNPs, Vaccines, Therapeutics, Formulation und Manufacturing
Orte
-
Primär
Semmelweisstr. 3
Planegg, 82152, DE
Beschäftigte von Ethris
Updates
-
We are thrilled to announce that Ethris received a total of €8 million in new funding: $5 million from Bill & Melinda Gates Foundation to prepare our lead candidate ETH47 for a phase 2 study and an additional €3 million investment by Cipla which had earlier invested €15 million in 2022. Learn more: https://lnkd.in/dSxiUwvc
-
-
We are happy to present at this year's International Cell&Gene Therapy China Summit. Our CEO, Carsten Rudolph, Dr., will speak about Ethris' mRNA and LNP platform on May 24th at 2:50pm.
-
-
Our CMO, Thomas Langenickel, will speak at this year's PCD Medical Board organized by the PCD Support UK in London, on May 17. His session will focus on Ethris' inhaled mRNA therapy for the treatment of people with PCD.
-
-
Our Chief Technology Officer, Christian Plank, will be speaking at TIDES USA in Boston, USA, on May 16 at 3:00pm. His session will focus on our recent advancements of RNA therapeutics for Primary Ciliary Dyskinesia.
-
-
We are excited to attend the LSX World Congress in London this week to present the progress of our programs and technology platform to potential partners and investors. Feel free to reach out and schedule a meeting with us!
-
-
We are attending the Formulation & Delivery by Oxford Global congress in London and our Director Technology Research Estelle Beguin, PhD is presenting Ethris' concepts and digital tools to accelerate the mRNA therapeutic screen.
-
-
We are attending the #ATiOConference2024 in Berlin presenting our ETH40 program for bone healing. Thank you for the opportunity Tobias Winkler and Michiel Bröker! Learn more: https://lnkd.in/djePeVW7
-
Ähnliche Seiten
Jobs durchsuchen
Finanzierung
Letzte Runde
Serie nicht bekannt5.000.000,00 $
Investor:innen